Batavia Insights
Living up to our mission to be a recognized Center of Excellence to the Life Sciences industry , we regularly share our knowledge through blogs and webinars.
Upcoming:
Driving down COGs of viral vector-based biopharmaceuticals
How do you keep cost of goods (COGs) for viral vector-based medicines within reason to develop a product that is both affordable and financially viable?
GMP viral vector and viral vaccine production: Is outsourcing to a CDMO the answer for your project?
Developing a successful viral vaccine or viral vector for use in a clinical setting is notoriously challenging. Unforeseen pitfalls and roadblocks in process development and scale-up can lead to costly delays. Worse still, a poorly developed process can be difficult...
Do fixed-bed bioreactors provide a solution to viral vector shortage?
A blog to guide you through some of our team’s experiences with fixed bed reactors for virus manufacturing.
Tackling the capacity bottleneck in downstream processing of viral vectors
Written by expert: Evert, Associate Director DSP With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand. A steady increase of product titers and the corresponding change in...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
